Systemic treatment for metastatic breast cancer: Combination chemotherapy

INTRODUCTION

Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [1-3]. Median overall survival approaches two years, with a range from a few months to many years [4].

The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy, consisting of chemotherapy, endocrine therapy, and/or biologic therapies, and supportive care measures [5,6].

The efficacy and dosing of combination chemotherapy regimens are presented here. General principles of management of metastatic breast cancer, selection of chemotherapy regimen, and use of single agent chemotherapy, biologic therapies, endocrine therapy, surgical options, and supportive care are discussed separately.

• (See "Systemic treatment for metastatic breast cancer: General principles".)
• (See "Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen".)
• (See "Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy".)
• (See "Systemic treatment for metastatic breast cancer: Single agent chemotherapy".)
• (See "Systemic treatment for metastatic breast cancer: Molecular targeted therapy".)
• (See "Metastatic breast cancer: Local treatment".)
• (See "Treatment of metastatic breast cancer in older women".)

INDICATIONS

Treatment principles for the use of chemotherapy in metastatic breast cancer are outlined here.